VC
ARQT icon

Vivo Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Vivo Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-433,585
Closed -$10.4M – 56
2021
Q3 		$10.4M Hold
433,585
– – 0.47% 37
2021
Q2 		$11.8M Sell
433,585
-310,785
-42% -$8.75M 0.51% 36
2021
Q1 		$21.5M Sell
744,370
-122,800
-14% -$3.83M 0.76% 29
2020
Q4 		$24.4M Sell
867,170
-246,095
-22% -$6.03M 1.09% 18
2020
Q3 		$32.6M Sell
1,113,265
-176,095
-14% -$4.7M 1.89% 12
2020
Q2 		$39M Sell
1,289,360
-397,167
-24% -$11.5M 2.8% 8
2020
Q1 		$50.3M Buy
+1,686,527
New +$45.3M 4.55% 4

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vivo Capital's ARQT Position: Q4 2021 in Review

Vivo Capital sold out of Arcutis Biotherapeutics (ARQT) in Q4 2021, closing a stake of 433,585 shares — an estimated $10.4M sold.

Vivo Capital first reported a position in ARQT in Q1 2020 and held it in 7 quarters. The position peaked at $50.3M in Q1 2020. 93 funds tracked by Wall St. Rank hold ARQT as of Q4 2021.

  • Vivo Capital reported no remaining Arcutis Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Vivo Capital sold 433,585 Arcutis Biotherapeutics shares in Q4 2021, an estimated $10.4M.
  • Vivo Capital first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 7 quarters.
  • Vivo Capital's Arcutis Biotherapeutics position peaked at $50.3M in Q1 2020.
  • 93 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2021.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.